Diversified Healthcare Trust vs Sabra Health Care REIT
DHC and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHC and SBRA compare
Sabra Health Care REIT is the larger company, worth 3.0 times as much as Diversified Healthcare Trust ($5.2B against $1.8B).
Sabra Health Care REIT grew revenue faster over the last twelve months (23.4% versus −3.8% for Diversified Healthcare Trust).
Sabra Health Care REIT keeps more of each dollar of sales as profit, with a net margin of 7.8% compared with −10.3% at Diversified Healthcare Trust.
Both pay dividends: Diversified Healthcare Trust yields 0.55% and Sabra Health Care REIT 7.3%.
Sabra Health Care REIT scores higher on the StockData Score (6 against 3 for Diversified Healthcare Trust), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHC | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $5.2B |
| Share price | $7.29 | $20.44 |
| Change, 1 year | 59.5% | 8.3% |
| Change, 5 years | 129% | 43.7% |
| Beta (5Y) | 1.11 | 0.46 |
| Employees | 600 | 58 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 0 | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | – | 73.0× |
| P/S | 1.2× (better) | 5.7× |
| P/B | 1.2× (better) | 1.8× |
| EV/EBITDA | 7.3× (better) | 12.7× |
| Fair value | $6.41 | $12.97 |
| Margin of safety | −13.6% (better) | −57.6% |
| Growth | ||
| Revenue growth (TTM) | −3.8% | 23.4% (better) |
| Revenue growth, 5Y average | −1.2% | 5.3% (better) |
| Net income growth (TTM) | – | −59.2% |
| EPS growth (TTM) | – | −61.1% |
| EPS growth, 5Y average | – | −0.91% |
| Profitability | ||
| Net margin | −10.3% | 7.8% (better) |
| Return on equity | −9.5% | 2.5% (better) |
| Financial health | ||
| Altman Z-score | 1.08 | 1.38 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.55% | 7.3% (better) |
| Payout ratio | – | 423% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | −26.0% | −2.3% (better) |
| Buyback yield | 0.16% | – |
| Shareholder yield | 0.71% | 7.3% (better) |
| Ownership | ||
| Held by institutions | 84.9% | 102% |
| Held by insiders | 15.2% | 1.9% |
| Insider net buying, 12 months | $97.8K (better) | −$4.7M |
| Short interest, % of float | – | 7.1% |
Go deeper
- DHC stock overview
- DHC income statement
- DHC valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.